** Shares of medical device maker Abbott Laboratories ABT.N up 1.8% at $130.92

** ABT says its study of a continuous glucose monitoring (CGM) device called FreeStyle Libre showed a 78% reduction in the risk of hospitalization for heart-related issues in people with diabetes

** Co says the study of the device was conducted using data from the Swedish National Diabetes Register

** Co says significant decrease is linked to the use of Libre biowearable technology compared to traditional blood glucose monitors

** Libre technology is used for patients to see their real-time glucose numbers, providing insights into how food, activity, or insulin impacts their glucose to help them make progress on their health goals

** Including session's moves, stock up 15.3% YTD

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))